DRTS

Alpha Tau Medical Ltd
  • Healthcare
  • Biotechnology
  • $1.30B market cap
Forecast run · Sep 14, 2026Upside rank 480 of 3,136

Model Signal

ForecastQ Daily Probabilities
56.2%
37.7%
42.2%

Analyst Consensus

Recommendation2.17/5 Buy
Last price$14.43
Price target$18.00
Implied move+24.7%
Analysts6

ForecastQ Portfolios

DRTS is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.

ForecastQ

Quantitative stocks signals powered by AI


The information provided is for educational purposes only and should not be considered financial advice. Past performance is not indicative of future results. ForecastQ is a research platform, a living documentation of an engineering experiment. We are not financial advisors.


© ForecastQ. All rights reserved.